The estimated Net Worth of Deepika Pakianathan is at least $6 Million dollars as of 22 August 2024. Deepika Pakianathan owns over 105,244 units of Theravance Biopharma Inc stock worth over $852,476 and over the last 11 years he sold TBPH stock worth over $5,149,077. In addition, he makes $0 as Independent Director at Theravance Biopharma Inc.
Deepika has made over 10 trades of the Theravance Biopharma Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 105,244 units of TBPH stock worth $151,551 on 22 August 2024.
The largest trade he's ever made was selling 906,178 units of Theravance Biopharma Inc stock on 31 May 2024 worth over $878,993. On average, Deepika trades about 84,710 units every 87 days since 2013. As of 22 August 2024 he still owns at least 105,244 units of Theravance Biopharma Inc stock.
You can see the complete history of Deepika Pakianathan stock trades at the bottom of the page.
Dr. Deepika R. Pakianathan Ph.D. serves as Independent Director of the Company. Prior to joining Delphi, Dr. Pakianathan was a Vice President in the healthcare group at J.P. Morgan where she was involved in several large healthcare M&A transactions and led public offerings for biotechnology companies. Prior to that, she was a biotechnology research analyst at Genesis Merchant Group. She worked as a postdoctoral scientist in the Immunology Department at Genentech Corporation from 1993 to 1997. Dr. Pakianathan received her Ph.D. and M.S. from Wake Forest University and her MSc and BSc from the University of Bombay . Dr. Pakianathan also currently serves on the boards of Calithera Biosciences, Inc., Karyopharm Therapeutics, Inc., and Mereo BioPharma Group, PLC.
Deepika Pakianathan is 52, he's been the Independent Director of Theravance Biopharma Inc since 2020. There are 19 older and 8 younger executives at Theravance Biopharma Inc. The oldest executive at Theravance Biopharma Inc is Burton Malkiel, 87, who is the Independent Director.
Deepika's mailing address filed with the SEC is 800 Chesapeake Dr, Redwood City, CA 94063, USA.
Over the last 11 years, insiders at Theravance Biopharma Inc have traded over $11,619,559 worth of Theravance Biopharma Inc stock and bought 4,008,513 units worth $29,986,832,769,275 . The most active insiders traders include Plc Gsk, Inc. Innoviva,, and Eli Samaha. On average, Theravance Biopharma Inc executives and independent directors trade stock every 57 days with the average trade being worth of $448,635. The most recent stock trade was executed by Eli Samaha on 7 August 2024, trading 999,800 units of TBPH stock currently worth $7,798,440.
theravance biopharma is a biopharmaceutical company with one approved product, vibativ® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.
Theravance Biopharma Inc executives and other stock owners filed with the SEC include: